Shares of AVI BioPharma dropped after results of a key clinical trial disappointed Wall Street. A partnership with a big drug firm could revive the stock.
From Barron's:
"The ink had barely dried on our latest issue when AVI BioPharma (ticker: AVII), the subject of a bullish article ("Waiting and Hoping," April 2), released data early Monday morning from a key clinical trial for its drug to treat Duchenne muscular dystrophy. The news was good, but not good enough to meet elevated expectations on Wall Street.
AVI's lead drug, called eteplirsen, is doing better than the stock, which could reward patient investors.
See the full story @ Barron's.
